ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

4-Methylmorpholine → [1-(6-{5-[6-(4-{2-[4-Cyano-1-(2-methoxycarbonylamino-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-naphthalen-2-yl]-1H-imidazol-2-yl}-5-aza-spiro[2.4]heptane-5-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester

HRID 2039225
ノート
印刷プレビュー

反応式

HRID 2039225 の反応式
[CH:1]1C=C[C:4]2N(O)N=[N:7][C:5]=2[CH:6]=1.Cl.Cl.Cl.[CH3:14][O:15][C:16](=[O:64])[NH:17][CH:18]([C:22]([N:24]1[CH:30]([C:31]2[NH:32][C:33]([C:36]3[CH:45]=[CH:44][C:43]4[C:38](=[CH:39][CH:40]=[C:41]([C:46]5[CH:51]=[CH:50][C:49]([C:52]6[NH:53][C:54]([CH:57]7[CH2:61][CH:60]([C:62]#[N:63])[CH2:59][NH:58]7)=[N:55][CH:56]=6)=[CH:48][CH:47]=5)[CH:42]=4)[CH:37]=3)=[CH:34][N:35]=2)[CH2:29][C:26]2([CH2:28][CH2:27]2)[CH2:25]1)=[O:23])[CH:19]([CH3:21])[CH3:20].CN1CC[O:69]CC1.C[CH2:73][O:74][C:75](C)=[O:76]>CN(C=O)C>[CH3:14][O:15][C:16](=[O:64])[NH:17][CH:18]([C:22]([N:24]1[CH:30]([C:31]2[NH:32][C:33]([C:36]3[CH:45]=[CH:44][C:43]4[C:38](=[CH:39][CH:40]=[C:41]([C:46]5[CH:51]=[CH:50][C:49]([C:52]6[NH:53][C:54]([CH:57]7[CH2:61][CH:60]([C:62]#[N:63])[CH2:59][N:58]7[C:4](=[O:69])[CH:5]([NH:7][C:75]([O:74][CH3:73])=[O:76])[CH2:6][CH3:1])=[N:55][CH:56]=6)=[CH:48][CH:47]=5)[CH:42]=4)[CH:37]=3)=[CH:34][N:35]=2)[CH2:29][C:26]2([CH2:27][CH2:28]2)[CH2:25]1)=[O:23])[CH:19]([CH3:21])[CH3:20]
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 79724-MethylmorpholineHCID 8857Ethyl AcetateHCID 757711-HydroxybenzotriazoleHCID 66620685(1-{6-[5-(6-{4-[2-(4-Cyano-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl]-naphthalen-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tris-hydrochloride

生成物 1

HCID 66620510
[1-(6-{5-[6-(4-{2-[4-Cyano-1-(2-methoxycarbonylamino-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-naphthalen-2-yl]-1H-imidazol-2-yl}-5-aza-spiro[2.4]heptane-5-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester
収率 49%

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

2-2-Methoxycarbonylamino-butyric acid (37 mg, 0.227 mmol) EDC-HCl (44 mg, 0.227 mmol) and HOBt (32 mg, 0.237 mmol) were combined in DMF (2 mL) and stirred for 20 min at RT. (1-{6-[5-(6-{4-[2-(4-Cyano-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-naphthalen-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester tris-hydrochloride (150 mg, 0.189 mg) was added, the reaction mixture was cooled to 0° C. and NMM (0.104 mL, 0.947 mmol) was added dropwise. After 1.5 h, the reaction mixture was warmed to RT. 30 min later, the mixture was diluted with EtOAc and washed with NaHCO3, then brine. The organic phase was dried over MgSO4, then filtered and concentrated. The resulting residue was purified by HPLC to afford the title compound (78 mg, 49%). MS (ESI) m/z 826 [M+H]+.

後処理

  1. temperaturethe reaction mixture was cooled to 0° C.
  2. waitAfter 1.5 h
  3. temperaturethe reaction mixture was warmed to RT
  4. washwashed with NaHCO3
  5. dry with materialThe organic phase was dried over MgSO4
  6. filtrationfiltered
  7. concentrationconcentrated
  8. customThe resulting residue was purified by HPLC

出典と根拠

ORDレコード
ord-70c8957884694775bead30a148c810d8
出典データセット
uspto-grants-2013_11
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08575118B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート